Clinicopathological and molecular comparison of eosinophilic solid and cystic renal cell carcinoma and TFEB ‐amplified renal cell carcinoma: a comprehensive study of 15 cases
Open Access
- 13 August 2026
- journal article
- Published by Wiley in Histopathology
- Vol. 89 (6) , 1083-1094
Abstract
Aims: Eosinophilic solid and cystic renal cell carcinoma (ESC‐RCC) and TFEB ‐amplified renal cell carcinoma ( TFEB ‐amplified RCC, a subset of TFEB‐ altered RCC) are rare eosinophilic renal cell tumours that can be difficult to distinguish on the basis of morphology and immunohistochemistry alone. In this study, we compared the clinicopathological and molecular features of these entities to identify distinguishing characteristics. Methods and results: Nine cases of ESC‐RCC and six cases of TFEB ‐amplified RCC from our institutional archives were evaluated for clinical, morphological, immunohistochemical and molecular features. Despite morphological overlap, each entity exhibited somewhat distinctive features. ESC‐RCC frequently exhibited solid and cystic architecture with tightly packed tubules, flocculent to coarsely granular cytoplasm with basophilic stippling and prominent admixed macrophages. In comparison, TFEB ‐amplified RCC more frequently demonstrated solid growth of pseudopapillae and loose tubules, dense eosinophilic granular cytoplasm without basophilic stippling, focally apical nuclei and extracellular magenta globules. However, neither morphology nor immunohistochemistry was sufficiently specific to completely distinguish these entities. Ancillary molecular testing identified pathogenic TSC1 or TSC2 gene variants in ESC‐RCC and TFEB gene locus amplification in TFEB ‐amplified RCC. Conclusions: Although ESC‐RCC and TFEB ‐RCC share overlapping morphological and immunohistochemical features, each demonstrates somewhat characteristic histological findings. Definitive distinction requires molecular testing to identify the underlying molecular alterations. As molecular testing assumes an increasingly important role in RCC diagnosis and classification, recognition of these rare entities and their overlapping and distinguishing features is essential for appropriate testing and accurate diagnosis.Keywords
This publication has 40 references indexed in Scilit:
- Morphology spectrum and molecular landscape in eosinophilic solid and cystic renal cell carcinomaHuman Pathology, 2026
- Evaluation of 3,606 renal cell tumors for TFE3 rearrangements and TFEB alterations via fluorescence in situ hybridization, next generation sequencing, and GPNMB immunohistochemistryHuman Pathology, 2025
- Renal Cell CarcinomaJAMA, 2024
- Prognosis and Clinicopathological Characters of Adult TFEB-Altered Renal Cell Carcinoma: A Single Center Experience of 18 CasesClinical Genitourinary Cancer, 2023
- The Role of the Pathologist in Renal Cell Carcinoma ManagementHematology/Oncology Clinics of North America, 2023
- Tissue Age Affects Antigenicity and Scoring for the 22C3 Immunohistochemistry Companion Diagnostic TestLaboratory Investigation, 2023
- The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular TumoursEuropean Urology, 2022
- New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasiaLaboratory Investigation, 2021
- Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing AssaysThe Journal of Molecular Diagnostics, 2017
- Diagnosis of copy number variation by Illumina next generation sequencing is comparable in performance to oligonucleotide array comparative genomic hybridisationGenomics, 2013